Get started
Author

Jinze Shen

Observed names: JINZE SHEN, Shen, Jinze
ORCID: 0000-0001-8822-2561
Observed ORCID: 0000-0001-8822-2561
OpenAlex ID: A5060884570
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
2023 · Jinze Shen, Qurui Wang, et al. · MedComm · 75
PDF
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
2022 · Jinze Shen, Chenhao Liang, et al. · Biomarker Research · 60
PDF
LINC00963: A potential cancer diagnostic and therapeutic target
2022 · Zijun Xie, Chenming Zhong, et al. · Biomedicine & Pharmacotherapy · 38
PDF
LINC00665: An Emerging Biomarker for Cancer Diagnostics and Therapeutics
2022 · Chenming Zhong, Zijun Xie, et al. · Cells · 32
PDF
Disulfidptosis-associated lncRNAs predict breast cancer subtypes
2023 · Qing Xia, Qibin Yan, et al. · Scientific Reports · 27
PDF
NINJ1: Bridging lytic cell death and inflammation therapy
2024 · Jinze Shen, Ruixiu Chen, et al. · Cell Death and Disease · 26
Novel Insights into miR-944 in Cancer
2022 · Jinze Shen, Qurui Wang, et al. · Cancers · 23
PDF
Emerging role of LINC00461 in cancer
2022 · Qiudan Zhang, Chenming Zhong, et al. · Biomedicine & Pharmacotherapy · 23
PDF
miR-1908 Dysregulation in Human Cancers
2022 · Jinze Shen, Yuchen Wu, et al. · Frontiers in Oncology · 22
PDF
LINC00520: A Potential Diagnostic and Prognostic Biomarker in Cancer
2022 · Qiudan Zhang, Jinze Shen, et al. · Frontiers in Immunology · 18
PDF
Unveiling the role of tRNA-derived small RNAs in MAPK signaling pathway: implications for cancer and beyond
2024 · Qurui Wang, Qinyuan Huang, et al. · Frontiers in Genetics · 17
PDF
Dysregulation of miR-411 in cancer: Causative factor for pathogenesis, diagnosis and prognosis
2022 · Mengsha Zou, Jinze Shen, et al. · Biomedicine & Pharmacotherapy · 14
PDF
LINC00324 in cancer: Regulatory and therapeutic implications
2022 · Qing Xia, Jinze Shen, et al. · Frontiers in Oncology · 13
Aberrant expression of microRNA-4443 (miR-4443) in human diseases
2022 · Yunan Mao, Jinze Shen, et al. · Bioengineered · 13
RhoJ: an emerging biomarker and target in cancer research and treatment
2024 · Jinze Shen, Xinming Su, et al. · Cancer Gene Therapy · 11
RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathy
2024 · Jinze Shen, Jianqiao Shentu, et al. · Clinical and Translational Medicine · 9
PDF
Exploring the multifaceted role of GCN1: Implications in cellular responses and disease pathogenesis
2024 · Xinying Zheng, Jinze Shen, et al. · Biomedicine & Pharmacotherapy · 9
Cuproptosis-associated ncRNAs predict breast cancer subtypes
2024 · Qing Xia, Jinze Shen, et al. · PLoS ONE · 9
The tumor suppressor role and ceRNA network of miR-1294 in cancer
2023 · YUNAN MAO, JINZE SHEN, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 9
PDF
MicroRNAs in adipose tissue fibrosis: Mechanisms and therapeutic potential
2024 · Mei Tian, Yang Zhou, et al. · Genes & Diseases · 8
Current and future perspectives on the regulation and functions of miR-545 in cancer development
2023 · Jinze Shen, Xinming Su, et al. · Cancer Pathogenesis and Therapy · 8
Exploring clinical indicator variations in stroke patients with multiple risk factors: focus on hypertension and inflammatory reactions
2024 · Jiejie Guo, Mei Tian, et al. · European journal of medical research · 6
PDF
Recent Insights Into Wnt‐Related tRNA‐Derived Fragments (tRFs) in Human Diseases
2025 · Jinze Shen, Qurui Wang, et al. · Journal of Cellular Biochemistry · 5
PDF
Current status and future perspectives in dysregulated miR-492
2023 · Jinze Shen, Jiahua Si, et al. · Gene · 5
LINC00319: Unraveling the spectrum from gene regulation to clinical applications in cancer progression
2023 · Xinming Su, Lingtao Yan, et al. · Gene · 4
Works count: 31
Citation count: 492
H-index: 13
I10-index: 15
Year
Topic
Type